Roche Holding AG


  • $1.8B drug deal to target cancer at genetic level Monday, 12 Jan 2015 | 8:05 AM ET

    Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."

  • US STOCKS-Futures climb after two-week drop Monday, 12 Jan 2015 | 7:35 AM ET

    *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-day decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis business Foundation Medicine, it said on Monday, signalling its determination to expand in cancer immunotherapy by paying a hefty mark-up on the U.S. company's current price. The deal will help the world's largest maker of cancer drugs push ahead in...

  • Great day for Foundation Medicine: CEO   Monday, 12 Jan 2015 | 7:29 AM ET
    Great day for Foundation Medicine: CEO

    CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.

  • Goldman Sachs: Watch out for energy M&A in 2015 Monday, 12 Jan 2015 | 7:14 AM ET
    A derrick hand removes the the plastic caps off the threaded ends of pipe used in the drilling process in Knox County, Ohio.

    Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine Inc for up to $1.18 billion, it said on Monday, in a move to bolster the Swiss drugmaker's personalised cancer treatments. The drugmaker said it will tender for about 15.6 million Foundation shares at $50 a share, worth up to about $780...

  • Roche to buy majority stake in Foundation Medicine Monday, 12 Jan 2015 | 1:21 AM ET

    Swiss drug maker Roche plans to acquire a majority stake in Foundation Medicine by buying a combination of outstanding and newly issued shares.

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • 23 andMe, co-founded by Anne Wojcicki, the wife of Google co-founder Sergey Brin, will contribute the genome sequencing and data from its Parkinson's disease community. Genentech, a unit of Roche Holding AG, will work to identify potential therapeutics based on that information. There is no cure for Parkinson's, which affects about 1 million people in the United...

  • Europe stocks close mixed after Greece vote fails Monday, 29 Dec 2014 | 10:34 AM ET

    European shares closed mixed on Monday, with Greece struck by renewed political uncertainty after its politicians failed to agree on a new president.

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • Europe closes mixed; Italian banks, health care weigh Friday, 19 Dec 2014 | 11:31 AM ET

    European shares closed mixed on Friday, with Italian banking stocks and the health care sector weighing on wider benchmarks.

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • Bad flu season: A prescription for growth? Wednesday, 10 Dec 2014 | 8:16 AM ET
    A mam receives an influenza shot from a Nurse Practitioner in the MinuteClinic at the CVS/pharmacy.

    The health-care sector tends to outperform the overall market during flu season. Who else stands to gain?

  • Fighting kids' cancer, one voucher at a time Friday, 21 Nov 2014 | 10:03 AM ET
    Jacob with his parents Mike Froman and Nancy Goodman, and brother Ben (Spring 2008)

    There are few new cancer drugs to treat kids, and not much research is being done.

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • US pulls approval for these Nexium, Valcyte generics Thursday, 6 Nov 2014 | 9:47 AM ET

    The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.

  • *Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte. *FDA said approvals were given "in error"- Ranbaxy. The FDA has also stripped Ranbaxy of tentative approval and six-month exclusivity for a copy of Roche Holding AG's antiviral Valcyte, a fresh blow to the Indian company that has been hit by a raft of regulatory bans over poor production quality.